» Articles » PMID: 20947930

Angiographic Thrombus Burden Classification in Patients with ST-segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention

Overview
Date 2010 Oct 16
PMID 20947930
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The presence of thrombus is associated with adverse clinical outcomes. Our aim was to develop a classification of thrombus burden (TB) in patients with ST-segment elevation myocardial infarction (STEMI).

Methods: We retrospectively analyzed 900 consecutive patients treated with percutaneous coronary intervention for STEMI. Drug-eluting stents were used in 90.1%. TB was graded (G) as G0 = no thrombus, G1 = possible thrombus, G2 = small [greatest dimension ≤ 1/2 vessel diameter (VD)], G3 = moderate (> 1/2 but < 2VD), G4 = large (≥ 2VD), G5 = unable to assess TB due to vessel occlusion. Patients with G5 were reclassified to a thrombus category after flow achievement either with a guidewire or a small (1.5 mm) balloon. The incidence of major adverse cardiac events (MACE) - defined as death, myocardial infarction and infarct-related artery revascularization - was computed using the Kaplan-Meier method.

Results: Median duration of follow-up was 18.5 months. G5 patients constituted 57.7% of all patients and reclassification was achieved in 97.9%. TB after reclassification was G0, 8.1%; G1, 19%; G2, 24.5%, G3,16.6%, G4, 30%, G5, 1.9%. The 2-year cumulative MACE-free survival was comparable in G1, G2, G3 (84.5%, 85.9% and 87% respectively, p = 0.83), while G0 (75.8%) and G4 (75%) did significantly worse (p = 0.001). After stratification in two groups of small (G0-3) and large (G4) TB, the latter was found to be an independent predictor for 2-year mortality (HR: 1.66, 95% CI: 1.04-2.68, p = 0.035) and MACE rate (HR: 2.04, 95% CI: 1.44-2.88, p < 0.001).

Conclusions: In patients with STEMI, TB can be reliably estimated in occluded infarct-related arteries. Large thrombus (≥ 2 VD) is a significant independent predictor for mortality and MACE.

Citing Articles

Long-term outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention without standard modifiable cardiovascular risk factors: findings from the OPT-CAD cohort.

Jiang Z, Liu H, Qiu M, Li J, Zhao W, Zhang D BMC Med. 2025; 23(1):112.

PMID: 39988674 PMC: 11849167. DOI: 10.1186/s12916-025-03933-2.


SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI.

Tamis-Holland J, Abbott J, Al-Azizi K, Barman N, Bortnick A, Cohen M J Soc Cardiovasc Angiogr Interv. 2024; 3(11):102294.

PMID: 39649824 PMC: 11624394. DOI: 10.1016/j.jscai.2024.102294.


Clinical and angiographic characteristics of patients with familial hypercholesterolemia presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Elmaghraby K, Abdel-Galeel A, Osman A, Hasan-Ali H, Abdelmegid M Sci Rep. 2024; 14(1):27098.

PMID: 39511296 PMC: 11543695. DOI: 10.1038/s41598-024-77656-4.


Uric Acid to Albumin Ratio as a Predictive Marker for Intracoronary Thrombus Severity in ST-Segment Elevation Myocardial Infarction (STEMI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI).

Duman H, Ipek E, Durak H, Sahin M, Ergul E, Yilmaz A Med Sci Monit. 2024; 30:e945832.

PMID: 39425464 PMC: 11497856. DOI: 10.12659/MSM.945832.


Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction.

De Luca G, Verburg A, Vant Hof A, Berg J, Kereiakes D, Coller B Biomedicines. 2024; 12(9).

PMID: 39335537 PMC: 11428685. DOI: 10.3390/biomedicines12092023.